Researchers have developed a prognostic model to identify which patients with diffuse large B-cell lymphoma (DLBCL) who have failed a prior autologous transplant would best benefit from a subsequent allogeneic transplant. The model was developed by analyzing the outcomes of 503 patients who underwent allogeneic HCT after disease progression/relapse following a prior autologous HCT whose outcomes were reported to CIBMTR. The model uses 3 prognostic factors to predict progression-free survival (PFS): Karnofsky performance status, interval from autologous HCT to allogeneic HCT, and chemoresistant disease status at time of allogeneic HCT. The CIBMTR prognostic model classified patients into four groups: low-, intermediate-, high-, or very high-risk, predicting 3-year PFS of 40%, 32%, 11% and 6%, respectively. Probabilities for 3-year OS were 43%, 39%, 19% and 11% in the low- to very high-risk groups, respectively.
Prognostic Model Predicts HCT Outcomes in Patients with DLBCL